Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Services
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development
  • One-Stop TIL Development
• CIK Therapy Development
  • One-Stop CIK Therapy Development
  • CIK Therapy Improvement

Cancer Vaccine GMP Manufacturing Services

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vaccine is a biological agent that enhances immunity to a particular disease. Over time, it has evolved from traditional prophylactic uses to more complicated therapeutic products. The cancer vaccine development is a pathway from discovery research to clinical evaluation of putative protective antigens. The process is unique, capital intensive and risky. Given the significance of safety with biologics, the vaccine industry is highly valued.

Fig.1 Life cycle of modern vaccine development. (Kaufmann, 2014)

There are a lot of challenges in the field of cancer vaccine development. it is essential to be in balance with cost, risks, and benefits besides finding safe and effective antigens, adjuvants, and delivery systems. Today, Creative Biolabs makes efforts to meet the steadily growing demands for novel cancer vaccines and accelerate vaccine design, development, and manufacturing through international collaboration and continuous innovation of technologies.

Cancer Vaccine Development at Creative Biolabs

Development of every vaccine starts at the exploratory stage. The goal of therapeutic cancer vaccines is to induce immunity activities against tumor-associated antigens (TAAs), which fall into two categories: tumor-specific shared antigens and tumor-specific unique antigens.

Cancer vaccine developments can be divided into two stages, pre-clinical and clinical development. Pre-clinical studies comprise laboratory and animal experiments. In the clinical stage, the vaccines are tested in humans and this process takes four phases and lasts for many years. Currently, we hope to introduce the following services to allow for a more streamlined and profitable vaccine development.

Creative Biolabs supports cancer vaccine development in both the pre-clinical and clinical phases. Our unique combination of expertise makes us an ideal partner to facilitate clients' vaccine research from the identification of potential targets, analysis of immune responses, to assessment in animal models.

GMP Manufacturing at Creative Biolabs

Cancer vaccines are made in the same way as other biologicals, but with higher standards, to ensure the purity and quality of final products. Every step from the beginning must be confirmed and the whole process of manufacture must be carried out in a clean, safe, and controlled environment.

In Creative Biolabs, cancer vaccines are prepared following Good Manufacturing Practices (GMP) and our cleanrooms are a part of GMP regulations for vaccine development. The circumstance of humidity, air, and temperature in this room are controlled along with the number of entering people simultaneously. According to the requirements, we can meet three GMP standards, including ISO, EU, and US-FDA, and we can deal with different issues in vaccine production.

1. GMP issues for upstream processing

General GMP concerns for upstream; Raw material preparation; Cell culture; Virus culture; Inactivation of microorganisms.

1. GMP issues for downstream processing

General GMP concerns for downstream; (ultra) Filtration techniques; (ultra) Centrifugation techniques; Sterile filtration and aseptic processing.

Highlights from Creative Biolabs

1. Guarantee: each cancer vaccine project is guaranteed by a SOP.
2. Comprehensive solutions: a complete pipeline with flexible options is provided for clients.
3. Top facilities & cleanrooms: every step is operated under the best conditions in an efficient manner.
4. Rich experience: our staffs have more than 10 years of experience in vaccine programs.

Vaccination remains the most cost-effective public health intervention, whose benefits extremely outweigh the costs. Here, Creative Biolabs can offer multiple products and services in the process development of cancer vaccines, GMP manufacturing, and analytical testing, as well as assist clients in pre-clinical and clinical research to support vaccine commercialization.

For more information on the solutions of vaccine-related services, please contact us by e-mail.

Reference

1. Kaufmann, S.H.; et al. Challenges and responses in human vaccine development. Curr Opin Immunol. 2014, 28: 18-26.